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Abstract
Overlapping histological features between benign and malignant lesions and a lack of firm diagnostic criteria for malignancy
result in high rates of inter-observer variation in the diagnosis of melanocytic lesions. We aimed to investigate the differential
expression of five miRNAs (21, 200c, 204, 205, and 211) in benign naevi (n = 42), dysplastic naevi (n = 41), melanoma in situ
(n = 42), and melanoma (n = 42) and evaluate their potential as diagnostic biomarkers of melanocytic lesions. Real-time PCR
showed differential miRNA expression profiles between benign naevi; dysplastic naevi and melanoma in situ; and invasive
melanoma. We applied a random forest machine learning algorithm to classify cases based on their miRNA expression profiles,
which resulted in a ROC curve analysis of 0.99 for malignant melanoma and greater than 0.9 for all other groups. This indicates
an overall very high accuracy of our panel of miRNAs as a diagnostic biomarker of benign, dysplastic, and malignant
melanocytic lesions. However, the impact of variable lesion percentage and spatial expression patterns of miRNAs on these
real-time PCR results was also considered. In situ hybridisation confirmed the expression of miRNA 21 and 211 in melanocytes,
while demonstrating expression of miRNA 205 only in keratinocytes, thus calling into question its value as a biomarker of
melanocytic lesions. In conclusion, we have validated some miRNAs, including miRNA 21 and 211, as potential diagnostic
biomarkers of benign, dysplastic, and malignant melanocytic lesions. However, we also highlight the crucial importance of
considering tissue morphology and spatial expression patterns when using molecular techniques for the discovery and validation
of new biomarkers.
Keywords microRNA .Molecular pathology .Melanoma . Dermatopathology
Introduction
Malignant melanoma has seen a rapid increase in incidence in
the last several decades, having risen by almost 50% in the last
decade alone, and is now the fifth most common cancer in the
UK [1]. The current gold standard method for the diagnosis of
melanocytic lesions is histological examination of tissue by
pathologists. However, this has been described as ‘one of the
most challenging and controversial fields in diagnostic histo-
pathology’ [2] due to overlapping histological features be-
tween benign and malignant lesions [3] and lack of firm diag-
nostic criteria for malignancy. This creates the potential for
both the over- and underdiagnosis of malignancy.
Dysplastic naevi represent a particular challenge.
Histologically, they have overlapping features with both be-
nign naevi at the mild end of the spectrum and melanoma at
the severe end. Accordingly, various studies have shown high
rates of interobserver variation in their histological diagnosis
[4, 5]. Of particular interest is a recent major study of 187
pathologists which concluded, in agreement with previous
smaller studies, that diagnosis of dysplastic naevi and early-
stage invasive melanoma was neither reproducible nor
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accurate [6]. Therefore, a reliable and objective molecular
marker to aid pathologists’ visual assessment of benign naevi,
dysplastic naevi, and melanoma would be of great clinical
value.
MicroRNAs (miRNAs) have been described as possessing
‘most of the characteristics of an ideal biomarker’: they are
sensitive and specific [7] and are stable in FFPE (formalin-
fixed paraffin-embedded) tissue [8–11]. Over the last decade,
the role of miRNAs as potential biomarkers in melanoma has
attracted significant attention, with miRNAs found to have
potential as diagnostic, prognostic, and predictive biomarkers,
as well as putative therapeutic targets [9, 10, 12–15].
miRNAs are short (up to 22 nucleotides), non-coding RNA
molecules present in all cells. They function in post-
transcriptional regulation of gene expression by binding to
the 3′ untranslated region (UTR) of mRNAs, blocking trans-
lation and sometimes accelerating mRNA degradation.
Depending on their target, miRNAs can function as both tu-
mour suppressors and tumour promoters. They provide a com-
plex and powerful means of regulating gene expression, with
computational predictions suggesting that they regulate one-
third of the genome [16].
Although differential expression of various miRNAs has
been demonstrated in benign and malignant melanocytic le-
sions, there is limited description of miRNA expression in
dysplastic naevi and one of their major differential diagnoses,
melanoma in situ [17–20], and studies which have been pub-
lished tend to suffer from small cohort sizes. Given the signif-
icant degree of diagnostic uncertainly generated by these le-
sions, we aimed to investigate the role of a panel of five
miRNAs as a potential diagnostic biomarker of benign naevi,
dysplastic naevi, melanoma in situ, and invasive melanoma.
Methods
Ethical approval and cohort selection
Ethical approval for access to FFPE (formalin-fixed paraffin-
embedded) archival tissue was gained from the NRS
BioResource and Tissue Governance Unit (SR961), and per-
mission to conduct the study was gained from ACCORD via
the Integrated Research Application System (IRAS). All cases
were identified by searching the NHS Lothian Pathology ar-
chive. All diagnoses were confirmed by dermatopathologist
review. Cases with insufficient lesional tissue for
macrodissection and molecular analysis, defined in this study
as lesions with a tumour percentage below 10%, were exclud-
ed. The final cohort consisted of 42 cases of melanoma; 42
cases of melanoma in situ; 41 cases of dysplastic naevi; 42
cases of benign common naevi; and 17 cases of normal skin.
All morphological subtypes of melanoma with a vertical
growth phase were included and detailed clinicopathological
features were recorded (summarised in Table 1, with full
details in ESM 1). Similarly, different morphological subtypes
of melanoma in situ were included, with the final cohort
consisting of 28 cases of melanoma in situ and 14 cases of
lentigo maligna. Because of the known high level of diagnos-
tic discordance of dysplastic naevi and the resulting potential
for inconsistent use of this term between pathologists, inclu-
s ion c r i t e r i a fo r th i s g roup were s t r i c t du r ing
dermatopathology review and were based on the WHO clas-
sification of skin tumours. All included cases had evidence of
cytological atypia and displayed classical architectural fea-
tures of dysplastic naevi including subepidermal fibroplasia;
bridging of adjacent rete ridges; lentiginous proliferation of
melanocytes; and shouldering in compound lesions. The final
cohort consisted of 13 cases with mild atypia, 13 with moder-
ate atypia, and 15 with severe atypia. Benign common naevi
were intradermal or compound naevi without features of con-
genital type neavus.
All eligible cases were reviewed by a molecular pathologist
and lesional areas for macrodissection were identified.
Nucleic acid extraction
Following microdissection, RNA was extracted using the
Recoverall Total Nucleic Acid Isolation Kit for FFPE
(AM1975, Thermo Fisher Scientific, UK) according to the
manufac ture r ’s pro tocol , wi th the exc lus ion of
deparaffinisation steps. In summary, samples were digested
in protease for 15 min at 50 °C (increased to 45 min for small
lesions) followed by 15min at 80 °C. Samples were incubated
with DNase mix for 30 min at room temperature prior to
further washing and elution. The concentration of RNA ex-
tract was measured using a Qubit Fluorometer with the high
sensitivity RNA assay.
Reverse transcription and real-time PCR
miRNA expression levels were assessed using the TaqMan®
small RNA assay protocol from Applied Biosystems. Assays
specific to miR-21 (hsa-miR-21, assay ID 00397); miR-200c
(hsa-miR-200c, assay ID 002300); miR-204 (hsa-miR-204,
assay ID 000508); miR-205 (hsa-miR-205, assay ID
000509); and miR-211 (hsa-miR-211, assay ID 000514) were
used, with U6 (RNU6B, assay ID 001093) as an endogenous
control (Thermo Fisher Scientific). Validation experiments
were performed for each assay with serial tenfold dilutions
of one sample, run in triplicate, to ensure the amplification
efficiency of the endogenous control (U6) and each target
miRNA was approximately equal. For all miRNA assays,
the plot of ΔCT against log input resulted in a semi-log re-
gression line with a slope < 0.1.
Reverse transcription was carried out using the TaqMan™
MicroRNA Reverse Transcription Kit (catalogue number
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4366596, Thermo Fisher Scientific). All RNA samples were
diluted in nuclease-free water to 1 ng in 5 μl, with each 15 μl
of reverse transcription reaction consisting of 5 μl of RNA,
7 μl of reverse transcription mastermix, and 3 μl of reverse
transcription primer.
Real-time PCR was carried out on 96-well plates using
TaqMan®Universal PCRMaster Mix II, No UNG (catalogue
number 4440043, Thermo Fisher Scientific) with each 20-μl
PCR reaction made up as follows: 1-μl TaqMan small RNA
assay; 1.33-μl product from reverse transcription reaction;
10-μl PCR mastermix; and 7.67-μl nuclease-free water.
Samples were run on an Applied Biosystems™ 7500 SDS
real-time PCR machine (Thermo Fisher Scientific). All reac-
tions were carried out in duplicate with negative controls.
In situ hybridisation
Chromogenic in situ hybridisation was carried out on a subset
of cases (benign naevi (n = 6), dysplastic naevi (n = 6; 3 with
mild atypia, 1 with moderate atypia, 2 with severe atypia),
melanoma in situ (n = 6), and melanoma (n = 6)) using
BaseScope™ assays (ACDbio) specific to each miRNA of
interest according to the manufacturer’s protocol. PPIB probes
were used as positive controls and DAPB as negative controls
(ESM 2 and 3).
In summary, for pre-treatment, slides were incubated with
5–8 drops of hydrogen peroxide at room temperature for
10 min and bathed in antigen retrieval solution within the
Braun Multiquick FS 20 steamer for 15 min. Following air
drying, a hydropic barrier was drawn around the tissue edge.
The next day, the slides were incubated with protease IV at
40 °C for 45 min, with re-application of the protease after
30 min, followed by incubation with the relevant probe at
40 °C for 2 h. The probes were amplified by the addition of
AMPS 0–6 in turn as follows: AMP 0 for 30 min at 40 °C;
AMP 1 for 15 min at 40 °C; AMP 2 for 30 min at 40 °C; AMP
3 for 30 min at 40 °C; AMP 4 for 15 min at 40 °C; AMP 5 for
45 min at room temperature; and AMP 6 for 15 min at room
temperature. Slides were then incubated with RNAScope fast
RED solution for 10 min at room temperature and counter-
stained with haematoxylin and lithium carbonate. Following
drying overnight, the spatial distribution of transcripts was
assessed by two independent pathologists.
Statistical analysis
The comparative CT method was applied to calculateΔΔCT
and expression fold changes in each miRNA. If the fold
change was between 0 and 1, indicating negative fold change
in expression, the formula − 1/2-ΔΔCT was used for linear
transformation. Statistical analysis of real-time PCR results
was performed usingMiniTab version 17. Relative expression
of each miRNA in each sample was calculated using the for-
mula 2-ΔCT, followed by log transformation (base 2).
Normality was confirmed with the Anderson-Darling tests
and probability plots. Welch’s ANOVA followed by the
Games-Howell pairwise comparison (with 95% confidence
intervals) was used to compare the expression levels of each
miRNA between groups. Adjusted p values are provided for
pairwise comparisons. Tests of equal variance followed by 1-
way ANOVA and Tukey’s pairwise comparison were used to
compare the expression levels of each miRNA in dysplastic
naevi with mild, moderate, and severe atypia. A two-tailed t
test was used to compare expression patterns in different mor-
phological subtypes of melanoma and melanoma in situ.
Correction for lesion percentage was performed by dividing
relative expression by the lesion percentage prior to log
transformation.
Decision tree modelling
Random forest with 100 trees was performed with log-
transformed relative expression data using Weka open-
source machine learning software version 3.6.13. Tenfold
Table 1 Summary of clinicopathological features of melanoma cohort. LVI, lymphovascular invasion
Morphological
subtype
Median
Breslow
thickness
Mean mitotic
count (per mm2)
Number with
ulceration
Number with
regression
Number with
precursor naevus
Number
with LVI
Number with
micro-satellites
Immune
response
18 nodular 3.6 7 18 5 full 3 3 0 2 brisk
18 superficial
spreading
1 partial 15
non--
brisk
2 desmoplastic 2
acral lentiginous
25 absent
1 lentigo maligna
melanoma
1 desmoplastic and
spindle cell
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cross-validation was used to avoid overfitting. Receiver oper-
ating characteristic (ROC) curve analysis was used to evaluate
overall accuracy as a diagnostic test.
Results
Expression of miRNAs in benign naevi, dysplastic
naevi, melanoma in situ, and melanoma
The expression of miRNA 21 was significantly increased
in melanoma compared with that in all other groups
(p < 0.001). Conversely, there was a significant reduction
in the expression of both miRNA 200c and 205 in mela-
noma compared with that in all other groups (p < 0.001).
The expression of miRNA 204 and 211 was significantly
higher in benign naevi compared with that in all other
groups (p < 0.001) (Fig. 1). The expression of miRNA
200c also showed significantly lower expression in mela-
noma in situ compared with that in dysplastic naevi
(p < 0.05) and benign naevi (p < 0.05). For miRNA 211,
expression was significantly reduced in melanoma in situ
compared with that in dysplastic naevi (p < 0.001), though
owing to a wide variation in expression in the melanoma
cohort, neither of these was significantly different from
melanoma. There were no significant differences in the
expression of miRNA 21 and 205 in benign naevi, dys-
plastic naevi, and melanoma in situ, and no significant
differences in the expression of miRNA 204 in dysplastic
naevi, melanoma in situ, and melanoma (Fig. 1).
Examination of miRNA expression in the form of fold
changes reveals a 3.41-fold increase in miRNA 21 in mel-
anoma compared with that in benign naevi, with almost 8-
and 7-fold reduced expression of miRNA 200c and 205,
respectively (Table 2). The greatest fold changes are seen
in miRNA 204 and 211, with almost 15- and 16-fold
reduced expression respectively in melanoma compared
with that in benign naevi. Large negative fold changes
in the expression of miRNAs-204 and 211 are also seen
in dysplastic naevi and melanoma in situ compared with
those in benign naevi.
Using 1-way ANOVAwith Tukey’s pairwise comparisons,
there was no significant difference between the expression
levels of all five miRNAs in dysplastic naevi with mild, mod-
erate and severe atypia. Two-tailed t tests showed no signifi-
cant differences in the expression of any miRNAs between
different morphological subtypes of malignant melanoma or
melanoma in situ.
Overall, dysplastic naevi and melanoma in situ showed a
similar pattern of expression, generally grouping with benign
naevi for miRNAs 21, 200c, and 205, and with melanoma for
miRNAs 204 and 211.
Expression of miRNAs in normal skin
miRNAs 21, 200c, and 205 showed a similar pattern of ex-
pression to that seen in benign and dysplastic naevi and were
significantly different from melanoma (Fig. 1; p < 0.001).
miRNA 200c expression in normal skin was also significantly
higher than that of melanoma in situ (p < 0.05). miRNA 204
and 211, however, showed significantly lower levels of ex-
pression in normal skin than they did in benign naevi and
dysplastic naevi (p < 0.001). miRNA 211 expression in nor-
mal skin was also significantly lower than that in the melano-
ma in situ and melanoma cohorts (p < 0.001), as was miRNA
204 expression but to a slightly lesser extent (p < 0.05).
Decision tree modelling
Random forest was able to correctly classify 36 out of 42
melanomas following tenfold cross-validation (Table 3).
Four of the six false-negative melanomas were classified as
melanoma in situ, resulting in only two cases which were
incorrectly classified as benign. There was one false-positive
melanoma which was a melanoma in situ, meaning no benign
lesions were incorrectly classified as malignant. Random for-
est gave very high ROC areas of 0.99 for melanoma, 0.97 for
benign naevi, 0.90 for dysplastic naevi, and 0.91 for melano-
ma in situ, indicating overall high accuracy of this panel of
miRNAs as a diagnostic test.
The impact of lesion percentage
One limitation of molecular testing with real-time PCR is that,
despite macrodissection, cell types other than melanocytes
will inevitably be incorporated into the samples. This effect
will be greater in cases with a low lesion percentage. After
macrodissection, the average lesion percentage for the dys-
plastic naevus cohort was 30% and 20.5% for the melanoma
in situ cohort. This compared to 65.6% for the melanoma
cohort and 62.5% for the benign naevus cohort. Despite the
likely impact of lesion percentage on the measured levels of
the miRNAs with real-time PCR, no adjustment for this was
identified in the published literature.
Following correction for lesion percentage, expression of
miRNA 21 remains significantly lower in benign naevi com-
pared to all other groups (p < 0.05), with expression in dys-
plastic naevi also significantly lower than melanoma and mel-
anoma in situ (p < 0.05, Fig. 2). Expression of both miRNA
200c and 205 remains significantly lower in melanoma com-
pared with that in all three other groups (p < 0.001), though
following correction expression is higher in dysplastic naevi
and melanoma in situ compared with that in benign naevi
(p < 0.005). Corrected expression of miRNA 204 and 211
was significantly lower in melanoma compared with that in
all other groups (p < 0.005) and significantly higher in benign
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naevi compared with that in all other groups (p < 0.001), with
intermediate expression in dysplastic naevi and melanoma in
situ. Random forest was able to correctly classify 37 out of 42
melanomas and 39 out of 42 benign naevi (Table 4). There
11
10
9
8
7
6
5
4
3
2
a
5.0
2.5
0.0
-2.5
-5.0
b
7.5
5.0
2.5
0.0
-2.5
-5.0
c
7
6
5
4
3
2
1
0
-1
-2
d
MelanomaMISDNBNNormal MelanomaMISDNBNNormal
MelanomaMISDNBNNormal MelanomaMISDNBNNormal
MelanomaMISDNBNNormal
10
5
0
-5
e
A A A A B
A A A B
C
A B C C C
A A A A B
A B C D C,D
R
el
at
iv
e 
ex
p
re
ss
io
n
R
el
at
iv
e 
ex
p
re
ss
io
n
R
el
at
iv
e 
ex
p
re
ss
io
n
R
el
at
iv
e 
ex
p
re
ss
io
n
R
el
at
iv
ee
xp
re
ss
io
n
Fig. 1 Boxplots of log-transformed relative expression of microRNAs
measured with real-time PCR. miRNAs 21 (a); 200c (b); 204 (c); 205
(d); and 211 (e) in normal skin, benign naevi (BN), dysplastic naevi (DN),
melanoma in situ (MIS), and melanoma. Letters indicate outcome of
Welch’s ANOVA followed by Games-Howell pairwise comparisons.
Groups which do not share a letter are significantly different from each
other (p < 0.05)
Table 2 Fold changes in
expression of each micro-RNA in
dysplastic naevi, melanoma in
situ, and melanoma compared
with benign naevi
mRNA 21 miRNA 200c miRNA 204 miRNA 205 miRNA 211
Dysplastic naevi − 1.39 − 1.07 − 11.04 1.20 − 6.33
Melanoma in situ − 1.30 − 1.58 − 16.99 − 1.12 − 12.56
Melanoma 3.41 − 7.57 − 14.96 − 6.66 − 15.96
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Fig. 2 Boxplots of log-transformed relative expression of microRNAs
measured with real-time PCR following correction for lesion percentage.
miRNAs 21 (a); 200c (b); 204 (c); 205 (d); and 211 (e) in benign naevi
(BN), dysplastic naevi (DN), melanoma in situ (MIS), and melanoma.
Letters indicate outcome ofWelch’s ANOVA followed byGames-Howell
pairwise comparisons. Groups which do not share a letter are significantly
different from each other (p < 0.05)
Table 3 Confusion matrix from
random forest with tenfold cross-
validation. Each horizontal row
shows how cases from each group
(BN, benign naevi;DN, dysplastic
naevi; MIS, melanoma in situ)
were classified based on the
miRNA expression data
Classified as
normal
Classified as
BN
Classified as
DN
Classified as
MIS
Classified as
melanoma
Normal 16 0 1 0 0
BN 0 39 2 1 0
DN 0 4 27 10 0
MIS 1 1 11 28 1
Melanoma 0 2 0 4 36
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were only two false-positive melanomas, one of which was a
melanoma in situ, and only two malignant lesions were
misclassified as benign naevi, one melanoma in situ, and
one melanoma. The overall ROC areas remained very high
for benign naevi andmelanoma, at 0.98 and 0.97, respectively,
and high for dysplastic naevi and melanoma in situ at 0.86 and
0.89, respectively.
In situ hybridisation
An important consideration with the above approach to
correcting for lesion percentage is that it assumes expression
of all miRNAs in lesional cells only, with differences between
groups reflective of differential expression in lesional cells. To
further assess the spatial expression of each miRNA, in situ
hybridisation with BaseScope™was performed on a subset of
cases. Due to low sensitivity of the probes resulting from the
short target sequences (direct communication with ACDbio)
and variable fixation times of clinical samples, we do not
believe the results of in situ hybridisation to be accurately
and reliably quantifiable. This technique has therefore only
been applied to demonstrate spatial expression of miRNAs,
and not as a method of quantifying miRNA expression.
Despite assay optimisation, the expression of miRNA 200c
and 204 remained too low to be reliably and consistently
visualised. miRNA 21 was widely expressed in invasive ma-
lignant melanocytes, with minimal expression in background
keratinocytes (Fig. 3a). miRNA 205 was consistently
expressed in keratinocytes in both benign and malignant le-
sions, with minimal expression detected in benign and malig-
nant melanocytes (Fig. 3b). miRNA 211, on the other hand,
was consistently expressed in benign and malignant melano-
cytes, with minimal expression detected in keratinocytes
(Fig. 3c). No miRNA expression was identified in other back-
ground cell types including lymphocytes and stromal cells.
Discussion
Our study has demonstrated significantly increased expression
of miRNA 21 and reduced expression of miRNAs 200c, 204,
205, and 211 in melanoma compared with that in benign
naevi. This is consistent with previously published data [9,
12, 14, 15]. The expression profiles of miRNA 21 and 211
in dysplastic naevi, using a significantly larger sample size
than previously published studies, are also largely consistent
with previously published results [18–20]. One exception is a
previous study which used fluorescent in situ hybridisation to
show high miRNA 211 expression was maintained in a cohort
of 21 dysplastic naevi, regardless of the degree of atypia, with
significantly reduced expression in invasive melanoma [17].
We also demonstrated high sensitivity and specificity of this
miRNA panel as a potential diagnostic test using a random
forest machine learning algorithm.
These results, however, should be interpreted in the context
of possible study limitations. It is recognised that both mela-
noma and melanoma in situ encompass a group of morpho-
logically and biologically diverse lesions. We included a co-
hort representative of the diversity of melanoma typically en-
countered in diagnostic pathology practice, within which we
did not find any significant differences in miRNA expression
between different morphological subtypes. However, this may
be appropriate for further analysis with a larger melanoma
cohort including selection for rarer subtypes.
In addition, it is noted that, despite the high ROC areas
resulting from the random forest algorithm, there remains
a level of misclassification between dysplastic naevi and
melanoma in situ which may impact clinical utility as a
diagnostic test. When the miRNA expression data was
scrutinised in greater detail, it was considered likely that
variable lesion percentages in different groups had an im-
pact on the final expression profiles. Correction for lesion
percentage resulted in miRNAs 21, 204, and 211 showing
an intermediate level of expression in dysplastic naevi and
melanoma in situ, in between that of benign naevi and
melanoma. Furthermore, miRNA 21 showed significantly
increased levels of expression from benign naevi to dys-
plastic naevi to melanoma in situ, with melanoma in situ
showing no significant difference from melanoma. This
provides further evidence of a correlation with increasing
degrees of atypia, as has been proposed previously [20].
For miRNAs 200c and 205, however, correction for lesion
percentage resulted in dysplastic naevi and melanoma in
situ showing a higher expression pattern than both mela-
noma and benign naevi, a finding which does not have
any obvious biological explanation.
Table 4 Confusion matrix from
random forest with tenfold cross-
validation following correction
for lesion percentage. Each hori-
zontal row shows how cases from
each group (BN, benign naevi;
DN, dysplastic naevi, MIS, mela-
noma in situ) were classified
based on the miRNA expression
data
Classified as BN Classified as DN Classified as MIS Classified as melanoma
BN 39 3 0 0
DN 3 27 10 1
MIS 1 13 27 1
Melanoma 1 1 3 37
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A further explanation for the corrected expression profiles
can be sought by examining expression patterns in normal
skin. Low expression of miRNA 204 and 211 in normal skin
compared with that of benign naevi suggests expression only
in melanocytes (which are found in low numbers in normal
skin). Conversely, a similar expression of miRNA 200c and
205 in normal skin and benign naevi suggests expression in
additional cell types such as keratinocytes. If there is, as
suspected, expression of some of the miRNAs in background
cells such as keratinocytes, this would clearly have an impact
on expression levels of miRNAs measured by real-time PCR.
It could also result in over-correction for lesion percentage, as
some or all of the measured miRNA would be originating
from background cells.
This hypothesis was tested using in situ hybridisation,
which demonstrated expression of miRNA 21 and 211
principally in melanocytes, with minimal expression de-
tected in keratinocytes. miRNA 205, however, was pri-
marily expressed in keratinocytes, with minimal expres-
sion detected in melanocytes. Given the identical expres-
sion profiles of miRNA 200c and 205 with PCR, it is
speculated that miRNA 200c may also be more highly
Melanoma Benign naevus
a
b
Melanoma Benign naevus
c
Melanoma Benign naevus
Fig. 3 miRNA 21 (a), miRNA
205 (b), and miRNA 211 (c)
expression in melanoma and
benign naevus samples using
BaseScope. a High expression of
miRNA 21 in invasive malignant
melanocytes with minimal
expression in benign
melanocytes, both with minimal
expression in background
keratinocytes. b Expression of
miRNA 205 in keratinocytes,
with minimal expression in
melanocytes. c Expression of
miRNA 211 in melanocytes, with
no significant expression in
keratinocytes. Black lines
represent the approximate
division between keratinocytes
and melanocytes. All photos × 20
magnification
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expressed in keratinocytes than melanocytes. Similarly,
given the identical expression profiles of miRNA 211
and 204, it is speculated that miRNA 204 may be
expressed principally in melanocytes.
Therefore, although miRNA 205 expression is clearly as-
sociated with melanoma, the reduced expression in melanoma
compared with that in all other lesion types with real-time
PCR could be explained by the reduced proportion of
keratinocytes in melanoma samples. Similarly, the expression
in keratinocytes would account for the relatively high
corrected expression in dysplastic naevi and melanoma in situ.
With miRNA 21 and miRNA 211 expressed principally in
melanocytes, their function as a potential biomarker of
melanocytic lesions is verified. However, this also makes it
difficult to be certain, when lesion percentage is not accounted
for, whether low expression in dysplastic naevi and melanoma
in situ with real-time PCR is due to downregulation with
atypia or malignant transformation, or due to low proportion
of melanocytes in these samples, or a combination of the two.
One recently published paper of particular interest exam-
ined miRNA expression in keratinocyte, melanocyte, and
melanoma cell lines [15]. miRNA 204 and 211 showed sig-
nificantly higher expression in cultured melanocytes than in
cultured keratinocytes, while miRNA 200c and 205 showed
significantly higher expression in cultured keratinocytes than
in cultured melanocytes. Our study provides further support of
these results by showing miRNA 211 expression principally
in melanocytes and miRNA 205 expression principally in
keratinocytes in human tissue samples.
The absence of significant expression of miRNA 205
in melanocytes could have considerable implications for
the interpretation of the literature suggesting a role as a
biomarker of melanoma, particularly as most papers ex-
amining miRNA expression profiles use techniques
which result in loss of spatial expression, including
miRNA microarrays, real-time PCR, and deep sequenc-
ing. Therefore, while supporting the potential for specif-
ic miRNAs including miRNA 21 and 211 to act as
biomarkers of melanocytic lesions, we also highlight
the crucial importance of consideration of tissue mor-
phology and spatial expression prior to application of
molecular techniques in the discovery and validation of
biomarkers using human tissue specimens.
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